Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus regorafenib in previously treated pMMR/MSS advanced colorectal cancer
ChiCTR2300071355Phase 2Recruiting
- Sponsor
- National Cancer Center/Chinese Academy of Medical Sciences
- Start
- May 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and regorafenib in colorectal cancer (CRC), sponsored by National Cancer Center/Chinese Academy of Medical Sciences. Primary endpoint: Overall response rate. Started May 2023; status: recruiting.
02
Drugs
cadonilimabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300071355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071355.